Trial Profile
Phase I study of two different schedules of lapatinib (GW572016) in combination with vinorelbine in advanced solid tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 18 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jul 2011 Planned End Date changed from 1 Oct 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 28 Jun 2010 Actual patient number (22) added as reported by ClinicalTrials.gov.